102 results
424B3
ATXI
Avenue Therapeutics Inc
2 Feb 24
Prospectus supplement
12:00am
to support the position that the benefits of their product outweigh the risks for the management of acute pain severe enough to require an opioid … of perjury that such holder is not a United States person as defined under the Code and is eligible for treaty benefits, or (ii) if the Common Stock
8-K
EX-4.2
25k0le
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-4.1
h191s3qbhzvltrxt2c
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-10.1
ianodokcs21k1l8tl
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-4.2
ot0qygtubq18g75b4 y2
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-4.1
uvv r3dlb8qm
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-10.2
8ztcsz9o6f
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
424B4
852d4xb icvdxs6vqx
2 Nov 23
Prospectus supplement with pricing info
9:00am